[[{“value”:”
Autobahn Therapeutics’ platform technology enables small molecules to selectively hit targets in the brain. In addition to a lead program ready for Phase 2 testing in two types of depression, the startup has a preclinical molecule with potential applications in neuroinflammatory disorders such as multiple sclerosis.
The post Fueled With $100M, Autobahn Therapeutics Gears Up for Depression Drug Clinical Trials appeared first on MedCity News.
“}]]
